---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-038499"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2026-05-27T20:30:22+00:00"
generated_at: "2026-05-27T20:38:07.487433+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Alnylam elects Benjamin F. Cravatt to board; shareholders re-elect directors and approve say-on-pay

## Summary
- Benjamin F. Cravatt, Ph.D. elected to Board effective June 1, 2026, filling newly created eleventh seat; term expiring 2028 annual meeting.
- Dr. Cravatt receives $75,000 annual cash retainer and initial stock option valued at $600,000 vesting over three years.
- At May 20, 2026 annual meeting, shareholders re-elected Class I directors Arbuckle, Greenstreet, and Sigal with over 95% votes for each.
- Say-on-pay approved with 111.8M for vs 8.6M against; PwC ratified as auditor with 119.8M votes for.

## SEC filing metadata
- accession: 0001628280-26-038499
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2026-05-27T20:30:22+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/alny-20260520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-038499
- JSON: https://secwatch.observer/filing/0001628280-26-038499.json
- Plain text: https://secwatch.observer/filing/0001628280-26-038499.txt

## Source-grounded claims
- claim_id: a7015ccdb8
  claim: Benjamin F. Cravatt was elected as Director at ALNYLAM PHARMACEUTICALS, INC..
  evidence_excerpt: Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.